Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

iNK Cell–Driven Strategies for Enhanced Multiple Myeloma ImmunotherapY

Objective

"Despite the transformative potential of CAR-T cell therapies, their widespread adoption is hindered by significant barriers, including prohibitive costs, severe toxicities, logistical challenges in manufacturing, and limited efficacy. The iN-KEY consortium aims to overcome these challenges by developing and clinically validating a next-generation, ""off-the-shelf"" immunotherapy platform for the treatment of Multiple Myeloma (MM). At the heart of this project is a disruptive platform based on engineered induced Pluripotent Stem Cells (iPSCs). This platform integrates several key innovations: 1) Highly immunocompatible, haplo-matched iPSC lines for broad allogeneic use; 2) A proprietary, high-capacity Docking Platform (DoP) for safe, precise, and multiplexed integration of effector genes, eliminating the risks associated with viral vectors; 3) A dual-targeting strategy combining a Chimeric Antigen Receptor (CAR) against BCMA and a Synthetic T-cell Activating Bifunctional (STAb) construct against CD19; and 4) A suite of additional effector genes to enhance cell persistence, homing, and safety. This therapeutic product will be manufactured using a scalable, automated, and feeder-free GMP process, with quality control enhanced by novel multi-omics and AI-driven methodologies to ensure product consistency and safety. The project will culminate in a first-in-human clinical trial to assess the safety and preliminary efficacy of the therapy in patients with relapsed/refractory Multiple Myeloma. By addressing the core challenges of scalability, safety, accessibility, and cost, the iN-KEY platform has the potential to unlock a new generation of complex, affordable, and highly effective immunotherapies, benefiting patients and healthcare systems across Europe and beyond."

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

HORIZON-RIA - HORIZON Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) HORIZON-HLTH-2025-01

See all projects funded under this call

Coordinator

BANC DE SANG I TEIXITS
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 2 475 046,25
Address
PASSEIG TAULAT 106-116
08005 Barcelona
Spain

See on map

Region
Este Cataluña Barcelona
Activity type
Research Organisations
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 2 475 046,25

Participants (12)